Soft tissue sarcoma (STS)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-SOFT-TISSUE-SARCOMA |
|---|---|
| Type | Disease |
| Aliases | Adult soft tissue sarcomaSTSSarcoma of soft tissuesSoft tissue sarcomaСаркома м'яких тканин |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | None declared |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_10 | C49.9 |
|---|---|
| icd_o_3_morphology | 8800/3 |
| oncotree_code | ST |
Notes
STS is a heterogeneous family of >50 subtypes. Systemic chemotherapy is moderately effective for most adult STS histologies. Doxorubicin is the most broadly active single agent. Response rates are modest (~10-26%). MDT discussion at a specialized sarcoma center is strongly recommended. Histology matters: GIST → imatinib (separate); bone sarcomas → separate; Ewing → VDC-IE; rhabdomyosarcoma → pediatric protocols.
Used By
Algorithms
ALGO-CASCADE-LFS-CARRIER-FAMILY-TESTING- ALGO-CASCADE-LFS-CARRIER-FAMILY-TESTINGALGO-CHOMPRET-2015-LFS- ALGO-CHOMPRET-2015-LFSALGO-CLASSIC-LFS-CRITERIA- ALGO-CLASSIC-LFS-CRITERIAALGO-STS-ADVANCED-1L- ALGO-STS-ADVANCED-1LALGO-STS-ADVANCED-2L- ALGO-STS-ADVANCED-2L
Disease
DIS-LEIOMYOSARCOMA- Leiomyosarcoma (LMS)DIS-OSTEOSARCOMA- OsteosarcomaDIS-RHABDOMYOSARCOMA- Rhabdomyosarcoma
Indication
IND-COSTELLO-CARRIER-INTENSIFIED- IND-COSTELLO-CARRIER-INTENSIFIEDIND-COSTELLO-CARRIER-SURVEILLANCE- IND-COSTELLO-CARRIER-SURVEILLANCEIND-DICER1-CARRIER-PREVENTION-OBSERVATION- IND-DICER1-CARRIER-PREVENTION-OBSERVATIONIND-DICER1-CARRIER-PREVENTION-SURVEILLANCE- IND-DICER1-CARRIER-PREVENTION-SURVEILLANCEIND-STS-ADVANCED-1L-AI- IND-STS-ADVANCED-1L-AIIND-STS-ADVANCED-1L-DOXORUBICIN- IND-STS-ADVANCED-1L-DOXORUBICININD-STS-ADVANCED-2L-GEMDOC- IND-STS-ADVANCED-2L-GEMDOCIND-STS-ADVANCED-2L-PAZOPANIB- IND-STS-ADVANCED-2L-PAZOPANIBIND-WERNER-CARRIER-INTENSIFIED- IND-WERNER-CARRIER-INTENSIFIEDIND-WERNER-CARRIER-SURVEILLANCE- IND-WERNER-CARRIER-SURVEILLANCE
Questionnaires
QUEST-SOFT-TISSUE-SARCOMA-1L-STUB- Soft tissue sarcoma — first line
Red flag
RF-CASCADE-LFS-FDR-POSITIVE- A first-degree relative of the patient (parent, sibling, or child) has a documented posit...RF-COSTELLO-CONFIRMED-CARRIER- Patient has a confirmed germline HRAS pathogenic variant — Costello syndrome (CS), an aut...RF-DICER1-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in DICER1 (RNase III endonuclea...RF-LI-FRAUMENI-FAMILY-HISTORY-SUSPICION- Family pedigree or personal history meeting criteria suggestive of Li-Fraumeni Syndrome (...RF-NF1-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in NF1 OR fulfillment of NIH/Be...RF-NF1-FAMILY-HISTORY-SUSPICION- Family pedigree pattern suggestive of germline NF1 carrier state in an asymptomatic indiv...RF-ROTHMUND-THOMSON-CONFIRMED-CARRIER- Confirmed biallelic germline pathogenic / likely-pathogenic variants in RECQL4 (RecQ-like...RF-WERNER-CONFIRMED-CARRIER- Confirmed biallelic germline pathogenic / likely-pathogenic variants in WRN (RECQL2; Wern...
Regimen
REG-DOXORUBICIN-IFOSFAMIDE-STS- Doxorubicin + ifosfamide (soft tissue sarcoma, AI regimen)REG-DOXORUBICIN-STS- Doxorubicin monotherapy (soft tissue sarcoma)REG-GEMCITABINE-DOCETAXEL-STS- Gemcitabine + docetaxel (soft tissue sarcoma)REG-PAZOPANIB-STS- Pazopanib (soft tissue sarcoma, 2L)
Sources
SRC-EORTC62012-JUDSON-2014- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment...SRC-PALETTE-VAN-DER-GRAAF-2012- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, place...SRC-SCHULTZ-DICER1-2018- DICER1 and Associated Conditions: Identification of At-Risk Individuals and Recommended S...SRC-STEWART-DICER1-REVIEW-2019- Neoplasm Risk Among Individuals With a Pathogenic Germline Variant in DICER1